Organon & Co. (NYSE:OGN) Stock Rating Lowered by JPMorgan Chase & Co.

Organon & Co. (NYSE:OGN) was downgraded by stock analysts at JPMorgan Chase & Co. from a “neutral” rating to an “underweight” rating in a research note issued on Friday, Briefing.com reports. They currently have a $20.00 target price on the stock, up from their prior target price of $18.00. JPMorgan Chase & Co.‘s price target points to a potential downside of 6.37% from the company’s current price.

Organon & Co. Stock Performance

OGN stock opened at $21.36 on Friday. The company has a market cap of $5.50 billion, a P/E ratio of 5.22, a price-to-earnings-growth ratio of 0.98 and a beta of 0.85. Organon & Co. has a 1 year low of $10.84 and a 1 year high of $23.10. The company has a debt-to-equity ratio of 60.05, a current ratio of 1.64 and a quick ratio of 1.17. The stock’s fifty day moving average price is $21.03 and its 200-day moving average price is $19.92.

Organon & Co. (NYSE:OGN) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. The firm had revenue of $1.61 billion for the quarter, compared to the consensus estimate of $1.61 billion. Organon & Co. had a negative return on equity of 840.29% and a net margin of 15.76%. The company’s revenue for the quarter was down .1% on a year-over-year basis. During the same period last year, the business posted $1.31 EPS. On average, equities analysts forecast that Organon & Co. will post 4.14 earnings per share for the current year.

Hedge Funds Weigh In On Organon & Co.

A number of institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Organon & Co. by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 30,789,850 shares of the company’s stock worth $578,849,000 after purchasing an additional 192,613 shares during the period. Massachusetts Financial Services Co. MA raised its holdings in Organon & Co. by 10.0% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 10,211,008 shares of the company’s stock worth $147,243,000 after purchasing an additional 930,708 shares during the period. LSV Asset Management raised its holdings in Organon & Co. by 47.3% in the 2nd quarter. LSV Asset Management now owns 6,610,768 shares of the company’s stock worth $136,843,000 after purchasing an additional 2,121,940 shares during the period. Nordea Investment Management AB raised its holdings in Organon & Co. by 26.9% in the 1st quarter. Nordea Investment Management AB now owns 3,970,328 shares of the company’s stock worth $74,563,000 after purchasing an additional 841,518 shares during the period. Finally, AQR Capital Management LLC raised its holdings in Organon & Co. by 39.8% in the 2nd quarter. AQR Capital Management LLC now owns 3,473,655 shares of the company’s stock worth $71,905,000 after purchasing an additional 988,336 shares during the period. 77.43% of the stock is owned by institutional investors.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.